Early research (Phase 1)Study completedNCT03448393
What this trial is testing
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Who this might be right for
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, B CellB-Cell Lymphoma+7 more
National Cancer Institute (NCI) 54